" /> Ensovibep - CISMeF





Preferred Label : Ensovibep;

NCIt definition : A designed ankyrin repeat proteins (DARPin)-based, tri-specific agent composed of three severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein (SP) receptor-binding domain (RBD) binding domains that bind to the same epitope region on the SARS-CoV-2 SP RBD and a human serum albumin (HSA)-binding domain, that can potentially be used for immunization against COVID-19. Upon administration, ensovibep specifically targets and binds to three epitopes in the same SARS-CoV-2 SP RBD region, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. Binding to three epitopes of the SARS-CoV-2 SP RBD may decrease the potential for viral escape through mutations. The HSA-binding domain binds to HSA which prolongs the half-life of the agent.;

UNII : PV6AA88RDU;

CAS number : 2451126-06-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2451126-06-8 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : MP 0420; MP-0420;

NCI Metathesaurus CUI : CL1648533;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
22/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.